PROK Stock Analysis: Buy, Sell, or Hold?
PROK - ProKidney Corp. Class A Ordinary Shares
$1.68
-0.03 (-2.05%)
▼
5d:
-9.95%
30d:
-14.1%
90d:
-15.4%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
PROK is down 10.8% this week, but smart money is accumulating calls. Top strike: $2 2026-06-18 with 13 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When PROK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called PROK this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PROK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PROK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PROK is currently trading at $1.68, which is considered oversold relative to its 30-day fair value range of $1.79 to $2.02.
Technical Outlook: Technically, PROK is in a downtrend. Immediate support is located at $1.59, while resistance sits at $1.99.
Market Sentiment: PROK has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.25 (+265.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PROK is in a downtrend. Immediate support is located at $1.59, while resistance sits at $1.99.
Market Sentiment: PROK has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.25 (+265.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.79 -
$2.02
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 265.5% below Wall St target ($6.25)
- CAUTION: 5-day price weakness (-9.9%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.79 -
$2.02
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.59
Resistance Level
$1.99
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.35
Wall Street Target
$6.25
(+265.5%)
Revenue Growth (YoY)
196.1%
Share & Embed Analysis
Last updated: May 15, 2026 3:03 PM ET
Data refreshes hourly during market hours. Next update: 4:03 PM
Data refreshes hourly during market hours. Next update: 4:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PROK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 57 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 55 HOLD |
